Welcome to our dedicated page for G1 Therapeutics news (Ticker: GTHX), a resource for investors and traders seeking the latest updates and insights on G1 Therapeutics stock.
G1 Therapeutics Inc. (GTHX) is a clinical-stage biopharmaceutical company pioneering novel therapies through its kinase-targeted drug discovery platform. This page provides centralized access to official news and developments related to their oncology pipeline, including treatments for extensive-stage small cell lung cancer and triple-negative breast cancer.
Investors and researchers will find timely updates on clinical trial progress, regulatory milestones, and strategic partnerships. Our curated feed includes verified information about small-molecule therapies, chemoprotective agents, and collaborative research initiatives aimed at improving cancer treatment outcomes.
Key categories cover FDA communications, trial phase results, intellectual property developments, and financial reporting. All content is sourced directly from company releases and reputable financial news outlets to ensure accuracy.
Bookmark this page to stay informed about G1 Therapeutics' advancements in reducing chemotherapy side effects and developing precision oncology treatments. Check regularly for updates on their clinical-stage assets and partnership-driven growth strategy.
G1 Therapeutics (Nasdaq: GTHX) announced the upcoming presentation of mature Phase 2 results on trilaciclib combined with sacituzumab govitecan (SG) at the ASCO 2024 Meeting from May 31 to June 4 in Chicago. The data indicates a positive impact on overall survival (OS) and tolerability in metastatic triple-negative breast cancer (mTNBC) compared to SG alone. The poster session detailing these findings will occur on June 2, 2024, from 9:00 AM to 12:00 PM CDT.
The abstract includes initial trial results shared in January 2024, with the new poster providing updated Phase 2 safety and efficacy outcomes.
G1 Therapeutics (Nasdaq: GTHX), a commercial-stage oncology company, announced that its Chief Medical Officer, Dr. Raj Malik, and Chief Commercial Officer, Andrew Perry, will participate in TD Cowen’s 5th Annual Oncology Innovation Summit.
The event will take place on May 29, 2024, at 8:30 AM EDT. A webcast of the fireside chat will be available on the company's Events & Presentations page.
G1 Therapeutics (Nasdaq: GTHX) and Deimos Biosciences, a Jupiter Bioventures portfolio company, announced a global licensing agreement for lerociclib, excluding the Asia-Pacific region. Lerociclib, a potent CDK4/6 inhibitor, will be developed for radioprotective uses. Jupiter Bioventures gains exclusive rights for clinical development, regulatory submissions, and commercialization in the US, Europe, Japan, and other markets excluding Asia-Pacific. G1 will receive 10% of Deimos' common stock and 20% royalties on annual net sales. The agreement aims to advance a solution in a high unmet need area.
G1 Therapeutics, Inc. announced the grant of inducement stock options and restricted stock units to a newly hired employee under the Amended and Restated 2021 Plan. The stock options are exercisable for 2,100 shares at $4.13 per share, with a ten-year term and vesting over four years. The RSUs consist of 1,050 units, vesting over four years as well. These awards were granted to induce the new employee to join G1 as per Nasdaq rules.
G1 Therapeutics reported $14.1 million in net revenue from sales of COSELA for Q1 2024, reaffirming $60-$70 million guidance for 2024. They announced updated efficacy results and final analysis from key trials. Cash runway extends to Q3 2025.
The financial results for Q1 2024 showed total revenue of $14.5 million, including $14.1 million from COSELA sales. Operating expenses decreased compared to Q1 2023. G1 reaffirmed its 2024 financial guidance of $60-$70 million in COSELA net revenue.
G1 Therapeutics, Inc. and Pepper Bio have announced a global licensing agreement for lerociclib, excluding Asia-Pacific, where Pepper Bio gains exclusive rights for clinical development, regulatory submissions, and commercialization in the US, Europe, Japan, and other global markets. Lerociclib, a selective CDK4/6 inhibitor, has shown promising efficacy in clinical studies, particularly in HR+/Her2- metastatic breast cancer and hepatocellular carcinoma. Pepper Bio's COMPASS platform identifies novel drug targets and will advance lerociclib to Phase 2 trials. G1 Therapeutics will receive mid-single-digit millions upfront and up to $135M in milestone payments, along with double-digit royalties on lerociclib sales.
FAQ
What is the current stock price of G1 Therapeutics (GTHX)?
What is the market cap of G1 Therapeutics (GTHX)?
